News

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer

Experienced, innovative biotech and pharma leader with demonstrated…

The first six companies enter the Deep Tech Lab – Quantum start-up accelerator at BII to unlock the potential in quantum science

BioInnovation Institute (BII), an international non-profit foundation…

Poolbeg Pharma plc – Directorate Change

30 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus

Paris, France, 28 November, 2023 – Astraveus SAS (“Astraveus”…

Poolbeg Pharma – Immunomodulator II patent granted in Japan

21 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…

Biocomposites expands its product portfolio with the launch of SYNICEM™ spacers in the UK

SYNICEM™ hip, knee and shoulder spacers are preformed…

Poolbeg Pharma – POLB 001 LPS Challenge Trial Data to be Presented at IUIS

POLB 001 - a potential blockbuster immunomodulator 16 November…

Versameb Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence

Versameb AG (“Versameb”), a pre-clinical stage company focused…

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Oxolife Appoints International Fertility Experts to its Scientific Advisory Board

Leading experts in fertility and human reproduction with…

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Trial expected to reach the primary endpoint of progression…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.